Jelinek D - Search Results

1

Activating mutations in the N- and K-ras oncogenes differentially affect the growth properties of the IL-6-dependent myeloma cell line ANBL6.

Billadeau D, Liu P, Jelinek D, Shah N, LeBien TW, Van Ness B. Billadeau D, et al. Among authors: jelinek d. Cancer Res. 1997 Jun 1;57(11):2268-75. Cancer Res. 1997. PMID: 9187131

2

Introduction of an activated N-ras oncogene alters the growth characteristics of the interleukin 6-dependent myeloma cell line ANBL6.

Billadeau D, Jelinek DF, Shah N, LeBien TW, Van Ness B. Billadeau D, et al. Among authors: jelinek df. Cancer Res. 1995 Aug 15;55(16):3640-6. Cancer Res. 1995. PMID: 7627974

3

Coexistence of aneuploid subclones within a myeloma cell line that exhibits clonal immunoglobulin gene rearrangement: clinical implications.

Jelinek DF, Ahmann GJ, Greipp PR, Jalal SM, Westendorf JJ, Katzmann JA, Kyle RA, Lust JA. Jelinek DF, et al. Cancer Res. 1993 Nov 1;53(21):5320-7. Cancer Res. 1993. PMID: 8221668

4

Identification of a global gene expression signature of B-chronic lymphocytic leukemia.

Jelinek DF, Tschumper RC, Stolovitzky GA, Iturria SJ, Tu Y, Lepre J, Shah N, Kay NE. Jelinek DF, et al. Mol Cancer Res. 2003 Mar;1(5):346-61. Mol Cancer Res. 2003. PMID: 12651908

5

Mechanisms of myeloma cell growth control.

Jelinek DF. Jelinek DF. Hematol Oncol Clin North Am. 1999 Dec;13(6):1145-57. doi: 10.1016/s0889-8588(05)70117-9. Hematol Oncol Clin North Am. 1999. PMID: 10626141 Review.

6

Dissection of the signalling requirements of interleukin-6-stimulated myeloma cell growth.

French JD, Tschumper RC, Jelinek DF. French JD, et al. Among authors: jelinek df. Acta Oncol. 2000;39(7):777-81. doi: 10.1080/028418600750063497. Acta Oncol. 2000. PMID: 11145432

7

Differential human multiple myeloma cell line responsiveness to interferon-alpha. Analysis of transcription factor activation and interleukin 6 receptor expression.

Jelinek DF, Aagaard-Tillery KM, Arendt BK, Arora T, Tschumper RC, Westendorf JJ. Jelinek DF, et al. J Clin Invest. 1997 Feb 1;99(3):447-56. doi: 10.1172/JCI119179. J Clin Invest. 1997. PMID: 9022078 Free PMC article.

8

Differential myeloma cell responsiveness to interferon-alpha correlates with differential induction of p19(INK4d) and cyclin D2 expression.

Arora T, Jelinek DF. Arora T, et al. Among authors: jelinek df. J Biol Chem. 1998 May 8;273(19):11799-805. doi: 10.1074/jbc.273.19.11799. J Biol Chem. 1998. PMID: 9565604 Free article.

9

Species D adenoviruses as oncolytics against B-cell cancers.

Chen CY, Senac JS, Weaver EA, May SM, Jelinek DF, Greipp P, Witzig T, Barry MA. Chen CY, et al. Clin Cancer Res. 2011 Nov 1;17(21):6712-22. doi: 10.1158/1078-0432.CCR-11-0968. Epub 2011 Sep 2. Clin Cancer Res. 2011. PMID: 21890454 Free PMC article.

10

Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab.

Zent CS, Call TG, Shanafelt TD, Tschumper RC, Jelinek DF, Bowen DA, Secreto CR, Laplant BR, Kabat BF, Kay NE. Zent CS, et al. Among authors: jelinek df. Cancer. 2008 Oct 15;113(8):2110-8. doi: 10.1002/cncr.23824. Cancer. 2008. PMID: 18759253 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

222 results

Search Page